ABUS vs PCG · P/E 5.4, rev $6.2M vs P/E 13, $37.68B cap
Arbutus Biopharma Corp (ABUS) versus PG&E Corp (PCG) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
PG&E Corp (PCG) is a utilities - regulated electric company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
PCG does not have a complete income-statement cache yet.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. PCG currently screens at market cap $37.68B and trailing P/E 13.3.
Not investment advice. Open the ABUS and PCG stock pages for the full models.
Not investment advice.